最新出版物
Phase 1B trial of Nab-paclitaxel plus gemcitabine, capecitabine, and cisplatin (PAXG regimen) in patients with unresectable or borderline resectable pancreatic adenocarcinoma.
Br J Cancer. 2016 Jul 26;115(3):290-6.
Reni M, et al.
扩展阅读
Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study.
Lancet Oncol. 2016 17 (11): 1521- 1532.
Baumert BG, Hegi ME, van den Bent MJ, von Deimling A, Gorlia T, Hoang-Xuan K, Brandes AA, Kantor G, Taphoorn MJ, Hassel MB, Hartmann C, Ryan G, Capper D, Kros JM, Kurscheid S, Wick W, Enting R, Reni M, Thiessen B, Dhermain F, Bromberg JE, Feuvret L, Reijneveld JC, Chinot O, Gijtenbeek JM, Rossiter JP, Dif N, Balana C, Bravo-Marques J, Clement PM, Marosi C, Tzuk-Shina T, Nordal RA, Rees J, Lacombe
扩展阅读
Health-related quality of life in patients with high-risk lowgrade glioma (EORTC 22033-26033): a randomised, openlabel, phase 3 intergroup study.
Lancet Oncol. 2016; 17 (11): 1533-1542
Reijneveld JC, Taphoorn MJ, Coens C, Bromberg JE, Mason WP, Hoang-Xuan K, Ryan G, Hassel MB, Enting RH, Brandes AA, Wick A, Chinot O, Reni M, Kantor G, Thiessen B, Klein M, Verger E, Borchers C, Hau P, Back M, Smits A, Golfinopoulos V, Gorlia T, Bottomley A, Stupp R, Baumert BG
扩展阅读
What treatment in 2017 for inoperable pancreatic cancers?
Ann Oncol. 2017
Taieb J, Pointet AL, Van Laethem JL, Laquente B, Pernot S, Lordick F, Reni M.
扩展阅读
Central nervous system gliomas. Crit Rev Oncol Hematol.
2017 May;113:213-234
Reni M, Mazza E, Zanon S, Gatta G, Vecht CJ
扩展阅读
Selecting patients for resection after primary chemotherapy for non-metastatic pancreatic adenocarcinoma.
Ann Oncol. 2017;28(11):2786-2792
Reni M, et al.
扩展阅读
Pancreatic ductal adenocarcinoma: State-of-the-art 2017 and new therapeutic strategies.
Cancer Treat Rev. 2017;60:32-43
Chiaravalli M, Reni M, O'Reilly EM.
扩展阅读
Consensus statement on mandatory measurements in pancreatic cancer trials (COMM-PACT) for systemic treatment of unresectable disease.
Lancet Oncol. 2018 Mar;19(3):e151-e160
Ter Veer E, van Rijssen LB, Besselink MG, Mali RMA, Berlin JD, Boeck S, Bonnetain F, Chau I, Conroy T, Van Cutsem E, Deplanque G, Friess H, Glimelius B, Oldstein D, Herrmann R, Labianca R, Van Laethem JL, Macarulla T, van der Meer JHM, Neoptolemos JP, Okusaka T, O'Reilly EM, Pelzer U, Philip PA, van der Poel MJ, Reni M, Scheithauer W, Siveke JT, Verslype C, Busch OR, Wilmink JW, van Oijen MGH, van
扩展阅读
Safety and efficacy of preoperative or postoperative chemotherapy for resectable pancreatic adenocarcinoma (PACT-15): a randomised, open-label, phase 2-3 trial.
Lancet Gastroenterol Hepatol. 2018 Jun;3(6):413-423.
Reni M, et al
扩展阅读
Biomarker-driven and molecularly targeted therapies for pancreatic adenocarcinoma.
Semin Oncol. 2018 Jun;45(3):107-115.
Zhen DB, Coveler A, Zanon S, Reni M, Chiorean EG
扩展阅读
Nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in metastatic pancreatic adenocarcinoma (PACT-19): a randomised phase 2 trial.
Lancet Gastroenterol Hepatol. 2018;3(10):691-697
Reni M, et al
扩展阅读
A randomised phase 2 trial of nabpaclitaxel plus gemcitabine with or without capecitabine and cisplatin in locally advanced or borderline resectable pancreatic adenocarcinoma.
Eur J Cancer. 2018;102:95-102
Reni M, et al
扩展阅读
Chemotherapy in elderly patients with pancreatic cancer: Efficacy, feasibility and future perspectives.
Cancer Treat Rev. 2019;72:1-6.
Macchini M, Chiaravalli M, Zanon S, Peretti U, Mazza E, Gianni L, Reni M.
扩展阅读
Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer.
NEJM 2019
Golan T, Hammel P, Reni M, et al
扩展阅读
